Progenics To Discontinue Hepatitis-C Program
Published: 08-Jun-2009
Company to focus on second generation HCV entry inhibitor portfolio
Progenics has announced the discontinuation of the development program for PRO 206, a pre-clinical compound for the treatment of hepatitis-C virus (HCV) infection.
The decision was made as part of a portfolio review, and is in line with the company's ongoing initiative to allocate resources to the most important programs in order to increase its operating efficiencies.
The company will instead focus on its second generation HCV entry inhibitor portfolio, and anticipates selection of a new development candidate in 2010.
Paul Maddon, Founder, CEO and Chief Science Officer of Progenics, said: Our research and development team has built a robust platform for HCV drug discovery. While our review indicated that PRO 206 did not satisfy the criteria for further development, our ongoing research and development efforts have yielded new compounds demonstrating comparable potency to PRO 206. These second-generation compounds also indicate a broader spectrum of activity in laboratory studies against the hepatitis C virus.
Delicious
Digg
Reddit
Stumble
Facebook
LinkedInNetwork Sites
Mail sent successfully
Suppliers To This Sector
Browse A-Z
World Courier
Offering Fully-Integrated GxP-Compliant Global Transport and Storage for the Pharmaceutical Industry...
WebWise Learning
Turning Information into Working Knowledge ...
Vetter Pharma International
High-Quality Aseptically Pre-Filled Injection Systems, Cartridges and Vials ...
Valsynthese
Hazardous Chemistry in Safe Hands ...
USB
Products from Affymetrix ...
Umicore Precious Metals Chemistry
Chemicals and Catalysts for Industrial Applications ...
White Papers
Browse A-Z
Water Treatment
From the control room to the downstream processing area and with an eye on utilities servi ...
A Vaccinne Bioassay Case Study – A Successful Strategic Outsourcing Model
Increasingly, pharma and biotech firms are searching for new drivers of revenue and profit ...
USB HotStart-IT for Real Time PCR
USB® Products from Affymetrix have a long-standing reputation in the life science marketpl ...
Enabling Drug Delivery Deal Making
Transdermal drug delivery: Time for a closer look. To find out more download this free whi ...
Automating Training Control Processes to Comply with FDA Requirements
Well-managed training programs minimize the risk of non-compliance and improve product qua ...
TNO Pharma Services: From Discovery to the Clinic
Our kinetics & metabolism experts can help you select and further develop your candidate d ...
